DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1902)

Microbiome | Special Topics | Multi-indication: Microbiome - (US/EU5)

Microbiome | Special Topics | Multi-indication: Microbiome - (US/EU5)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon - May 2019 

Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant investments in this space, notably including multiple deals made through the Janssen Human Microbiome Institute and several multimillion dollar IPOs, including Seres Therapeutics and Evelo Biosciences. However, no microbiome-based therapy has yet received an FDA approval, although FMT is widely accepted for use in recurrent C. difficile infections and proprietary microbiome-based candidates are proceeding to Phase III clinical trials. With new therapies entering Phase II clinical trials, and more in early-phase research and development, it is becoming increasingly important to understand the potential of this emerging group of therapies.


· How do physicians familiar with microbiome research evaluate the potential of microbiome-based therapies, and what therapies are seen as most promising?

· What therapy areas will benefit from microbiome-based therapies? How will such therapies fit into the existing treatment algorithms?

· Will particular mechanisms of administration be more successful? Will live bacteria or microbiome-derived small molecules be effective?

· What potential hurdles will such therapies face in the market? How do physicians anticipate regulatory agencies will respond?


United States, EU5

Primary Research

  • 10 interviews with thought-leading specialists, including oncologists, gastroenterologists, and metabolic specialists.
  • Supported by survey data collected for this and other DRG research


High-level overview of relevant epidemiological figures for selected indications. FORECAST Drug-level sales in 2024 and 2029


Phase II: 5 drugs; coverage of select preclinical and Phase I products


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This special report is based on a modified Disease Landscape & Forecast template, with abbreviated epidemiological data and current treatment analysis, but including expanded content covering ongoing early-phase research and regulatory concerns specific to live bacterial products.

Table of contents

  • Multi-indication: Microbiome - (US/EU5)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Kristine Mackin, PhD
  • Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

Purchase Report

Recent reports:
You may also be interested in: